A TARGETED APPROACH FOR TREATING HEMATOLOGICAL CANCERS AND BEYOND
Kurome Therapeutics is a late preclinical stage company that is developing a series of potent and differentiated IRAK1/4, panFLT3 inhibitors. Our robust preclinical data package includes:
The IRAK1/4 Signaling Complex Lies At A Critical Signaling Node That Drives Cancer Cell Survival Through Multiple Mechanisms
CHECK OUT OUR LATEST NEWS
Check out our news page for the latest information on technology and more!